In conclusion, while there is a sound scientific basis for the potential benefits of GLP-1/GIP receptor agonists in T1D with overweight or obesity, the clinical evidence is still evolving, and larger, more rigorous clinical trials are necessary to establish their efficacy, optimal usage protocols, and safety in this specific patient population
This shift reduces the contribution of FAO to the total energy expenditure
In a small prospective proof-of-concept trial [100], authors recruited nine diabetic patients with asthma who were given the GLP-1 RA liraglutide
So what is the clinicians role
Additionally, Semaglutide may also affect the release of certain neurotransmitters in the brain, which can contribute to the development of headaches
They may reduce how much you want to eat, but nutrition quality still matters